BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Kidney tumors AND CD79B, ENSG00000007312, 974, P40259, IGB, B29 AND Prognosis
5 results:

  • 1. 53 years old is a reasonable cut-off value to define young and old patients in clear cell renal cell carcinoma: a study based on TCGA and SEER database.
    Tang F; Lu Z; He C; Zhang H; Wu W; He Z
    BMC Cancer; 2021 May; 21(1):638. PubMed ID: 34051738
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Metallothioneins may be a potential prognostic biomarker for tumors: A Prisma-compliant meta-analysis.
    Wang L; Xin F; Lin N; Wang Y; Liu X; Liu J
    Medicine (Baltimore); 2018 Dec; 97(52):e13786. PubMed ID: 30593161
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. [Comparison of efficacy between sorafenib and sunitinib as first-line therapy for metastatic renal cell carcinoma and analyze prognostic factors for survival].
    Cai W; Yuan YC; Li MY; Kong W; Dong BJ; Chen YH; Zhang J; Xue W; Huang YR; Zhou LX; Huang JW
    Zhonghua Zhong Liu Za Zhi; 2018 May; 40(5):384-389. PubMed ID: 29860767
    [No Abstract]    [Full Text] [Related]  

  • 4. De Ritis ratio (aspartate transaminase/alanine transaminase ratio) as a significant prognostic factor after surgical treatment in patients with clear-cell localized renal cell carcinoma: a propensity score-matched study.
    Lee H; Lee SE; Byun SS; Kim HH; Kwak C; Hong SK
    BJU Int; 2017 Feb; 119(2):261-267. PubMed ID: 27226065
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Pancreatic metastasis from renal cell carcinoma.
    D'Ambra M; Ricci C; Casadei R; Minni F
    Urologia; 2011 Oct; 78 Suppl 18():5-8. PubMed ID: 22139800
    [TBL] [Abstract] [Full Text] [Related]  


    of 1.